[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease]

Arch Esp Urol. 1995 Dec;48(10):979-83.
[Article in Spanish]


Objectives: The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis.

Methods: Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.

Results: Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.

Conclusions: Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.

Publication types

  • Case Reports
  • English Abstract
  • Review

MeSH terms

  • Aged
  • Bromocriptine / adverse effects*
  • Dopamine Agonists / adverse effects*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Pergolide / adverse effects*
  • Retroperitoneal Fibrosis / chemically induced*


  • Dopamine Agonists
  • Pergolide
  • Bromocriptine